Cansino Biologics Inc. Announces Initiation of Phase III Clinical Trial and Completion of First Patient Enrollment in Phase I Clinical Trial for Recombinant Poliomyelitis Vaccine in Indonesia - Marketscreener.com
| CJH Stock | 3.66 0.12 3.17% |
Slightly above 61% of CanSino Biologics' investor base is looking to short. The analysis of current outlook of investing in CanSino Biologics suggests that many traders are alarmed regarding CanSino Biologics' prospects. CanSino Biologics' investing sentiment can be driven by a variety of factors including economic data, CanSino Biologics' earnings reports, geopolitical events, and overall market trends.
CanSino |
Cansino Biologics Inc. Announces Initiation of Phase III Clinical Trial and Completion of First Patient Enrollment in Phase I Clinical Trial for Recombinant Poliomyelitis Vaccine in Indonesia Marketscreener.com
Read at news.google.com
 |
CanSino Biologics Fundamental Analysis
We analyze CanSino Biologics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CanSino Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CanSino Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Outstanding
Shares Outstanding Comparative Analysis
CanSino Biologics is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
CanSino Biologics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with CanSino Biologics stock to make a market-neutral strategy. Peer analysis of CanSino Biologics could also be used in its relative valuation, which is a method of valuing CanSino Biologics by comparing valuation metrics with similar companies.
Peers
CanSino Biologics Related Equities
| H4L1 | JSC Halyk | 2.94 | ||||
| 0VD | UNIVERSAL MUSIC | 1.58 | ||||
| WA4 | Warner Music | 1.32 | ||||
| 8QC | TYSNES SPAREBANK | 0.74 | ||||
| MOB | Monster Beverage | 0.14 | ||||
| 63TA | Tencent Music | 1.75 | ||||
| SC3 | ScanSource | 2.98 |
Additional Tools for CanSino Stock Analysis
When running CanSino Biologics' price analysis, check to measure CanSino Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CanSino Biologics is operating at the current time. Most of CanSino Biologics' value examination focuses on studying past and present price action to predict the probability of CanSino Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CanSino Biologics' price. Additionally, you may evaluate how the addition of CanSino Biologics to your portfolios can decrease your overall portfolio volatility.